Harpoon Therapeutics Inc logo

HARP - Harpoon Therapeutics Inc Share Price

$11.42 -0.0  -0.3%

Last Trade - 8:24pm

Sector
Healthcare
Size
Small Cap
Market Cap £229.3m
Enterprise Value £110.4m
Revenue £4.64m
Position in Universe 3091st / 6323
Bullish
Bearish
Unlock HARP Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

HARP Revenue Unlock HARP Revenue

Net Income

HARP Net Income Unlock HARP Revenue

Normalised EPS

HARP Normalised EPS Unlock HARP Revenue

PE Ratio Range

HARP PE Ratio Range Unlock HARP Revenue

Dividend Yield Range

HARP Dividend Yield Range Unlock HARP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
HARP EPS Forecasts Unlock HARP Revenue
Profile Summary

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct, or TriTAC, platform, the Company is developing a pipeline of T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Its TriTAC product candidate, HPN424, is focused on the treatment of metastatic castration-resistant prostate cancer, or mCRPC.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated March 19, 2015
Public Since February 8, 2019
No. of Shareholders: 33
No. of Employees: 61
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 24,944,089
Free Float (0.0%)
Eligible for
ISAs
SIPPs
HARP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for HARP
Upcoming Events for HARP
Thursday 7th May, 2020 Estimate
Q1 2020 Harpoon Therapeutics Inc Earnings Release
Monday 3rd August, 2020 Estimate
Q2 2020 Harpoon Therapeutics Inc Earnings Release
Similar to HARP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.